coli glyceraldehyde-3-phosphate dehydrogenase and isocitrate lysase, respectively (Anjem and Imlay, 2012), and 1020 M 1 s 1 for assorted eukaryotic tyrosine phosphatases (Denu and Tanner, 1998)
Sandall, A
the compositions comprise at least about 1 M, at least about 2 M, at least about 3 M, at least about 4 M, at least about 5 M, at least about 6 M, at least about 7 M, at least about 8 M, at least about 9 M, at least about 10 M, at least about 11 M, at least about 12 M, at least about 13 M, at least about 14 M, at least about 15 M, at least about 16 M, at least about 17 M, at least about 18 M, at least about 19 M, at least about 20 M, at least about 21 M, at least about 22 M, at least about 23 M, at least about 24 M, at least about 25 M, at least about 26 M, at least about 27 M, at least about 28 M, at least about 29 M, at least about 30 M, at least about 1 M, at least the compositions comprise at least about 16.4 mM of cofactor or precursor thereof (e.g., niacinamide)

Localized Action with Minimal Systemic Exposure Because it primarily acts within the GI tract, oral BPC-157 minimizes systemic exposure , making it appealing for individuals focused on gut restoration rather than full-body repair